INTRODUCTION {#s1}
============

Worldwide, lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is one of the leading causes of cancer-related deaths \[[@R1]\], and its mortality rate ranks top in China \[[@R2]\]. Moreover, NSCLC is a major histological type accounting for 80%--85% \[[@R1]\]. Because of its high mortality, substantial efforts have been made to prolong overall survival (OS). Initially, conventional platinum-based chemotherapy prolonging a median survival of 8 to 10 months was regarded as a standard regimen, but it hit a plateau with low response of only 20 to 35% and intolerable toxicities \[[@R3]\]. Fortunately, over past decades, the finding of some driver genes in NSCLC, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and kirsten rat sarcoma viral oncogene homolog (KRAS), was a major breakthrough in lung cancer field \[[@R4]\]. Accordingly, molecular targeted therapy, characterized by high efficacy and low toxicity directing to driver gene mutations, has yielded favorable effects on advanced NSCLC. Compared with conventional platinum-based chemotherapy in NSCLC harboring EGFR mutation or ALK rearrangement, targeted agents such as erlotinib and crizotinib have obtained a durable response and extended OS \[[@R5], [@R6]\]. However, for patients with EGFR wild type or drug resistance to TKIs, the efficacy was poor \[[@R7]\].

Recently, immune checkpoints including programmed death-ligand 1 (PD-L1), programmed death 1 (PD-1), have made waves in anticancer immunotherapy. Some studies exhibited that PD-L1 expressed on the surface of tumor cells, including in NSCLC, melanoma, breast cancer \[[@R8], [@R9]\]. PD-1/PD-L1 inhibitors, such as nivolumab and atezolizumab, achieved a considerable success in dealing with advanced NSCLC via blocking PD-1/PD-L1 \[[@R10], [@R11]\]. However, due to the advantaged population of PD-L1 inhibitors remained inconclusive, the response rates were discrepant that inspired oncologists to identify the appropriate individuals. Recently, some researchers investigated the correlation between PD-L1 expression and driver gene mutations, but it remained to be clarified \[[@R12]--[@R22]\]. Although three previous studies \[[@R23]--[@R25]\] had evaluated the correlation between positive PD-L1 expression and OS, no meta-analysis had been performed on the correlation between positive PD-L1 expression and driver gene mutations. On that account, we performed this study to evaluate the correlation, to screen the potential advantaged population of PD-L1 inhibitors and to find preliminary evidence in favor of the strategy of PD-L1 inhibitors plus target agents.

RESULTS {#s2}
=======

Study selection and characteristics {#s2_1}
-----------------------------------

After initial comprehensively searching from PubMed, EMBASE and Cochrane Library databases, 622 potential relevant articles were found, whereas 595 (235 duplications and 360 irrelevant articles) were excluded. Then, another 16 articles were further removed after screening full-text for the following reasons: 8 for insufficient data, 4 for driver genes unavailable and 4 for the same population. Eventually, 11 articles incorporating 3128 cases were identified. The flow chart of literature searching and the clinical characteristics of included studies were listed in Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}, respectively. Of these eligible studies, 5 were from China \[[@R17], [@R18], [@R20]--[@R22]\], 2 from Japan \[[@R16], [@R19]\], 2 from Australia \[[@R12], [@R13]\], 1 from USA \[[@R15]\] and 1 from Italy \[[@R14]\]. The year of publication ranged from 2014 to 2016. The sample size of the included studies ranged from 100 to 678. With regard to the histological type of NSCLC, 7 studies \[[@R15]--[@R19], [@R21], [@R22]\] evaluated adenocarcinoma (ADC), and the other studies \[[@R12]--[@R14], [@R20]\] involved ADC, squamous cell cancer, large cell cancer and mixed types. Among these studies, positive PD-L1 expression appeared in 28.3% of male, 30.3% of female, 36.0% of never smoking, 32.1% of former/current smoking, 28.9% of ADC and 18.6% of non-ADC. Considering the diversity of PD-L1 antibodies, including 4 studies \[[@R14], [@R17], [@R21], [@R22]\] used polyclonal antibodies (PoAbs) and 7 \[[@R12], [@R13], [@R15], [@R16], [@R18]--[@R20]\] utilized monoclonal antibodies (McAbs), we conducted further subgroup analyses based on antibody types (McAbs or PoAbs). The details of PD-L1 antibodies in each study and the cut-off of PD-L1 were listed in Table [2](#T2){ref-type="table"}.

![Flow chart for study selection](oncotarget-08-23517-g001){#F1}

###### The characteristics of these included studies

  Study ID                            Country     Number of samples   Gender    Smoking status                Histology   PD-L1 expression   EGFR status   KRAS status   ALK status   OS
  ----------------------------------- ----------- ------------------- --------- ----------------------------- ----------- ------------------ ------------- ------------- ------------ -----------------
  Cooper et al, 2015 \[[@R13]\]       Australia   678                 477/201   NA/NA                         276/402     628/50             237/33        182/88        267/3        HR and 95% CI
  Ji et al, 2016 \[[@R17]\]           China       100                 51/49     74/26                         100/0       60/40              40/60         90/10         NA/NA        HR and 95% CI
  Yang et al, 2014 \[[@R21]\]         China       163                 54/109    132/31                        163/0       98/65              66/97         155/8         3/160        survival curves
  D\'Incecco et al, 2015 \[[@R14]\]   Italy       123                 66/57     (never/former)94/current 17   82/41       55/68              67/56         95/28         113/10       survival curves
  Song et al, 2016 \[[@R18]\]         China       385                 198/187   235/150                       385/0       199/186            180/205       369/16        367/18       HR and 95% CI
  Zhang et al, 2014 \[[@R22]\]        China       143                 59/84     94/49                         170/0       73/70              67/76         136/7         134/9        survival curves
  Tang et al, 2015 \[[@R20]\]         China       170                 93/77     113/57                        145/25      58/112             71/99         NA/NA         NA/NA        HR and 95% CI
  Inamura et al, 2016 \[[@R16]\]      Japan       268                 142/126   112/156                       268/0       225/43             97/93         168/21        258/10       HR and 95% CI
  Takada et al, 2016\[[@R19]\]        Japan       417                 205/212   218/199                       417/0       332/85             123/112       NA/NA         NA/NA        HR and 95% CI
  Huynh et al, 2016 \[[@R15]\]        USA         261                 90/171    NA/NA                         261/0       166/95             207/54        153/108       257/4        survival curves
  Ameratunga et al, 2016 \[[@R12]\]   Australia   420                 297/123   27/376                        185/235     320/100            397/23        341/79        NA/NA        survival curves

Abbreviation: M/F: male/female; ADC: adenocarcinoma; non-ADC: non-adenocarcinoma; N/P: negative/positive; NA: unavailable.

###### The details of PD-L1 antibodies in each study and the cut-off of PD-L1

  Study ID                    Method   Types of antibody   PD-L1 antibodies                                                                                           The cut-off of PD-L1
  --------------------------- -------- ------------------- ---------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cooper et al, 2015          IHC      monoclonal          Mouse monoclonal anti-PD-L1 primary antibody (Merck; clone22C3)                                            PD-L1 staining intensity ≥ 50%
  Ji et al, 2016              IHC      polyclonal          Mouse polyclonal antibodies (Abcam, Cambridge, UK, ab174838)                                               cases with staining intensity ≥ 2 in more than 5% of tumor cells were considered as positive
  Yang et al, 2014            IHC      polyclonal          Rabbit anti-PD-L1 antibody (Proteintech Group Inc. Chicago, IL, USA, 17952-1-AP)                           membranous staining was present in ≥ 5% of the cells.
  D\'Incecco et al, 2015      IHC      polyclonal          Rabbit primary antibodies PD-L1 (CD274) ab58810 (Abcam, Cambridge, UK)                                     all cases with staining intensity ≥ 2 in more than 5% of tumour cells were considered as positive
  Song et al, 2016            IHC      monoclonal          Rabbit anti-PD-L1 primary antibody (Proteintech Group Inc, Chicago, IL, USA, Catalog number: 66248-1-Ig)   positive, when membranous staining was present in ≥ 5 % of the cells.
  Zhang et al, 2014           IHC      polyclonal          primary anti-PD-L1 antibody (SAB2900365; Sigma-Aldrich)                                                    positive cut off quickscore of ≥ 3
  Tang et al, 2015            IHC      monoclonal          Rabbit monoclonal anti-human antibody (E1L3N™, Cell Signaling Technology, Danvers, MA)                     A 5% proportion of membrane-positive tumor cells which were defined as H-score ≥ 5 have been used as cutoff for PD-L1 positivity
  Huynh et al, 2016           IHC      monoclonal          Monoclonal antibody (E1L3N, Cell Signaling Technology, Danvers, MA)                                        Positive PD-L1 expression on tumor cells for 5% cutoff
  Inamura et al, 2016         IHC      monoclonal          anti-PD-L1 rabbit monoclonal antibody (clone: E1L3N, Cell Signaling Technology, Danvers, MA, USA)          A score of 5% or more was categorized as PD-L1-positive
  Ameratunga M, et al, 2015   IHC      monoclonal          Anti-PD-L1 rabbit IgG (E1L3N) cat \# 13684, Cell Signaling Technology                                      PD-L1 positivity was defined as \> 5% cells with membranous staining of intensity 2. Strong positivity was defined as of 50% cells with membranous staining of intensity 2.
  Takada et al, 2016          IHC      monoclonal          Rabbit monoclonal antibody (clone SP142, Spring Bioscience, Ventana, Tucson, AZ, USA).                     Positive PD-L1 protein expression for 5% cutoff

Overall and subgroup analyses {#s2_2}
-----------------------------

### Correlation between positive PD-L1 expression and clinical characteristics {#s2_2_1}

Overall analyses revealed no significant correlation between positive PD-L1 expression and gender (RR = 1.16; 95% CI, 0.95--1.42; *P* = 0.15, Figure [2A](#F2){ref-type="fig"}) \[[@R12]--[@R22]\]; smoking status (RR = 0.79; 95% CI, 0.56--1.11; *P* = 0.17, Figure [2B](#F2){ref-type="fig"}) \[[@R12], [@R16]--[@R22]\]; histological types (RR = 0.94; 95% CI, 0.63--1.41; *P* = 0.77, Figure [2C](#F2){ref-type="fig"}) \[[@R12]--[@R14], [@R20]\], respectively. Meanwhile, no significant correlation between positive PD-L1 expression and gender, smoking status, histological types were observed in subgroup analyses on the studies using PD-L1 McAbs (Figure [3](#F3){ref-type="fig"}), on the studies using PD-L1 PoAbs (Figure [4](#F4){ref-type="fig"}), on Chinese cohort studies (Figure [5](#F5){ref-type="fig"}).

![The correlation between positive PD-L1 expression and gender (**A**), smoking status (**B**), histology (**C**) in overall analyses.](oncotarget-08-23517-g002){#F2}

![The correlation between positive PD-L1 expression and gender (**A**), smoking status (**B**), histology (**C**) in the studies using PD-L1 McAbs.](oncotarget-08-23517-g003){#F3}

![The correlation between positive PD-L1 expression and gender (**A**), smoking status (**B**) in the studies using PD-L1 PoAbs.](oncotarget-08-23517-g004){#F4}

![The correlation between positive PD-L1 expression and gender (**A**), smoking status (**B**) in Chinese cohort studies.](oncotarget-08-23517-g005){#F5}

Correlation between positive PD-L1 expression and driver genes {#s2_3}
--------------------------------------------------------------

### Positive PD-L1 expression and EGFR status {#s2_3_1}

The pooled analysis of 11 studies \[[@R12]--[@R22]\] showed no significant relationship between positive PD-L1 expression and EGFR mutation (RR = 0.74; 95% CI, 0.52--1.06; *P* = 0.10, Figure [6A](#F6){ref-type="fig"}), although positive PD-L1 expression occurred more frequently in EGFR mutation studies than EGFR wild type studies (37.4% versus 30.6%). However, considering the fact that obvious heterogeneity existed among these eligible studies (*I*^2^ = 85%, *P* \< 0.00001), subgroup analyses were conducted based on the studies using PD-L1 McAbs or PoAbs, and on Chinese cohort studies. The outcomes demonstrated that in the studies using PD-L1 McAbs, positive PD-L1 expression more frequently occurred in EGFR mutation group than in wild type group (RR = 0.51; 95% CI, 0.28--0.93; *P* = 0.03, Figure [6B](#F6){ref-type="fig"}) \[[@R12], [@R13], [@R15], [@R16], [@R18]--[@R20]\] while the same results were not observed in subgroup analyses on the studies using PD-L1 PoAbs (RR = 1.06; 95% CI, 0.72--1.55; *P* = 0.77, Figure [6C](#F6){ref-type="fig"}) \[[@R14], [@R17], [@R21], [@R22]\], and on Chinese cohort studies (RR = 1.08; 95% CI, 0.84--1.38; *P* = 0.56, Figure [6D](#F6){ref-type="fig"}) \[[@R17], [@R18], [@R20]--[@R22]\].

![The correlation between positive PD-L1 expression and EGFR status in overall analysis (**A**), in the studies using PD-L1 McAbs (**B**), in the studies using PD-L1 PoAbs (**C**) and in Chinese cohort studies (**D**).](oncotarget-08-23517-g006){#F6}

Positive PD-L1 expression and ALK status {#s2_4}
----------------------------------------

Seven studies (1613 cases) \[[@R13]--[@R16], [@R18], [@R21], [@R22]\] were applied to assess the correlation between positive PD-L1 expression and ALK status. No heterogeneity existed in these studies (*I*^2^ = 0%, *P* = 0.75), thus a fixed-effect model was employed. The pooled result indicated that positive PD-L1 expression was not associated with ALK status (RR = 1.02; 95% CI, 0.75--1.38; *P* = 0.91, Figure [7A](#F7){ref-type="fig"}). Moreover, all subgroup analyses suggested that no significant correlation between positive PD-L1 expression and ALK status in the studies using PD-L1 McAbs (RR = 1.04; 95% CI, 0.68--1.59; *P* = 0.84, Figure [7B](#F7){ref-type="fig"}) \[[@R13], [@R15], [@R16], [@R18]\], in the studies using PD-L1 PoAbs (RR=0.99; 95% CI, 0.64--1.52; *P* = 0.95, Figure [7C](#F7){ref-type="fig"}) \[[@R14], [@R21], [@R22]\], and in Chinese cohort studies (RR = 1.05; 95% CI, 0.73--1.52; *P* = 0.79, Figure [7D](#F7){ref-type="fig"}) \[[@R18], [@R21], [@R22]\].

![The correlation between positive PD-L1 expression and ALK status in overall analysis (**A**), in the studies using PD-L1 McAbs (**B**), in the studies using PD-L1 PoAbs (**C**) and in Chinese cohort studies (**D**).](oncotarget-08-23517-g007){#F7}

Positive PD-L1 expression and KRAS status {#s2_5}
-----------------------------------------

Nine studies \[[@R12]--[@R18], [@R21], [@R22]\] incorporating 2054 cases were assigned to analyze the relationship between positive PD-L1 expression and KRAS status. A fixed-effect model was employed due to no evident heterogeneity (*I*^2^ = 7%, *P* = 0.38), and the outcome revealed a significant correlation between PD-L1 expression and KRAS status (RR = 1.26; 95% CI, 1.06--1.50, *P* = 0.010, Figure [8A](#F8){ref-type="fig"}). Furthermore, the result mentioned above was obtained in the studies using PD-L1 McAbs (RR = 1.32; 95% CI, 1.06--1.65, *P* = 0.01, Figure [8B](#F8){ref-type="fig"}) \[[@R12], [@R13], [@R15], [@R16], [@R18]\]. However, subgroup analyses on the studies using PD-L1 PoAbs \[[@R14], [@R17], [@R21], [@R22]\] and on Chinese cohort studies \[[@R17], [@R18], [@R21], [@R22]\] displayed that no significant correlation between PD-L1 expression and KRAS status, (RR = 1.13; 95% CI, 0.87--1.48; *P* = 0.36, Figure [8C](#F8){ref-type="fig"}), (RR = 1.04; 95% CI, 0.74--1.47; *P* = 0.83, Figure [8D](#F8){ref-type="fig"}), respectively.

![The correlation between positive PD-L1 expression and KRAS status in overall analysis (**A**), in the studies using PD-L1 McAbs (**B**), in the studies using PD-L1 PoAbs (**C**) and in Chinese cohort studies (**D**).](oncotarget-08-23517-g008){#F8}

Correlation between positive PD-L1 expression and OS {#s2_6}
----------------------------------------------------

Ten studies \[[@R13]--[@R22]\] (2708 patients) exploring the correlation between PD-L1 expression and OS were included in this study. A random-effects model was employed because of obvious heterogeneity (*I*^2^ = 77%, *P* \< 0.00001). The result indicated that positive PD-L1 expression tended to be associated with poor OS, despite no statistical significance (HR=1.31, 95% CI, 0.90--1.90; *P* = 0.15, Figure [9A](#F9){ref-type="fig"}). Additionally, subgroup analyses on the studies using PD-L1 McAbs \[[@R13], [@R15], [@R16], [@R18]--[@R20]\] and on the studies using PD-L1 PoAbs \[[@R14], [@R17], [@R21], [@R22]\] showed that positive PD-L1 expression was not associated with OS (HR = 1.46, 95% CI, 0.92--2.32; *P* = 0.11, Figure [9B](#F9){ref-type="fig"}), (HR = 1.08, 95% CI, 0.54--2.17; *P* = 0.84, Figure [9C](#F9){ref-type="fig"}), respectively. However, in Chinese cohort studies \[[@R17], [@R18], [@R20]--[@R22]\], the result implied that positive PD-L1 expression was significantly related to poor OS (HR = 1.75, 95% CI, 1.36--2.24; *P* \< 0.0001, Figure [9D](#F9){ref-type="fig"}) without obvious heterogeneity (*I*^2^ = 0%, *P* = 0.68).

![The correlation between positive PD-L1 expression and OS in overall analysis (**A**), in the studies using PD-L1 McAbs (**B**), in the studies using PD-L1 PoAbs (**C**) and in Chinese cohort studies (**D**).](oncotarget-08-23517-g009){#F9}

Publication bias {#s2_7}
----------------

The funnel plot of all included studies (Figure [10](#F10){ref-type="fig"}) indicated that no remarkable publication bias existed in this study, suggesting that the obtained results were reliable.

![The funnel plot of the correlation between positive PD-L1 expression and gender](oncotarget-08-23517-g010){#F10}

DISCUSSION {#s3}
==========

To the best of our knowledge, this study involving 11 eligible studies (3128 cases) is the first meta-analysis to focus on the correlation between positive PD-L1 expression and driver genes in NSCLC. Our study revealed that positive PD-L1 expression tended to occur more frequently in female, never smoking, ADC, EGFR mutation and ALK positive, but no significant association between them. Interestingly, there was a significant correlation between positive PD-L1 expression and KRAS status. Meanwhile, concerning the diversity of PD-L1 antibodies, further subgroup analyses based on the studies using PD-L1 McAbs or PoAbs were implemented. And the results showed that positive PD-L1 expression was significantly associated with KRAS status and EGFR status in the studies using PD-L1 McAbs, but not in the studies using PD-L1 PoAbs. Furthermore, we also conducted another subgroup analyses on Chinese cohort studies, which revealed that positive PD-L1 expression was associated with only OS, but not with other parameters.

KRAS mutation is one of the most common driver genes in NSCLC, but the aim of designing therapeutic regimen for lung ADCs harboring KRAS mutations has far proven elusive. Our study demonstrated that positive PD-L1 expression had a significant correlation with KRAS status. The result mentioned above was obtained in the studies using PD-L1 McAbs, while it did not occur in the studies using PD-L1 PoAbs and in Chinese cohort studies. One reason for the inconsistent results between overall and subgroup analyses might be the diversity of races (4 studies were from China, 1 from Japan, 2 from Austria, 1 from Italy and 1 from USA), because KRAS mutation was low expression in Chinese population \[[@R26]\]. The other reason might be the distinct features between McAbs and PoAbs. Generally, McAbs has a higher specificity while PoAbs possesses a higher sensitivity, especially in identifying low-abundance proteins. Recently, some oncologists also conducted studies to investigate the relationship between positive PD-L1 expression and KRAS status, finding that immune markers (including PD-L1) decreased in KRAS mutant tumors harboring STK11/LKB1 alterations but increased in KRAS mutant tumors bearing TP53 alterations \[[@R27]\]. Moreover, Pivarcsi et al reported that the activation of EGFR and KRAS pathways might be involved in immune response suppression in murine melanoma models \[[@R28]\]. On that account positive PD-L1 expression had a significant correlation with KRAS status, thereby, PD-L1 inhibitors might be a potential option in managing NSCLC harboring KRAS mutation.

With respect to the relationship between PD-L1 expression and EGFR status, some studies showed that the activation of EGFR pathway might up-regulate PD-L1 expression \[[@R29]\]. Our study revealed that PD-L1 expression was significantly associated with EGFR status in the studies using PD-L1 McAbs but not in the studies using PD-L1 PoAbs. The discrepancy probably be attributed to the diversity of antibodies, however, the mechanism remained to be elaborated.

Additionally, this study revealed that PD-L1 expression had no significant correlation with ALK status in both overall and subgroup analyses. However, Ota et al showed that EML4-ALK rearrangements and downstream signaling pathways could induced PD-L1 expression in NSCLC models \[[@R30]\]. Thus, the association between positive PD-L1 expression and ALK status still needs better designed pre-clinical trials and clinical trials to further clarify.

Furthermore, subgroup analyses demonstrated that positive PD-L1 expression was significantly associated with OS in Chinese cohort studies but not in the studies using PD-L1 McAbs or PoAbs. This differences may attribute to the diversity of races, the definition of positive/negative PD-L1 expression, the various therapeutic regimen, the duration of follow-up, the baseline characteristics as well as the potential bias of several HRs which were extracted from Kaplan-Meier curves.

Nevertheless, we also encountered some limitations: firstly, the sample size of participants was not substantial, only 11 studies containing 3128 cases, thus, more large scales studies including various races were required to further determine the correlation between PD-L1 expression and drive genes; subsequently, all eligible articles were published in English, and other languages were not included, which may be a potential bias; finally, the obvious heterogeneity among these eligible studies would affect the stability of statistical analyses to some extent, despite the fact that subgroup analyses had lowered the heterogeneity.

Accordingly, PD-L1 inhibitors probably was a potential promising option to manage advanced NSCLC harboring KRAS mutation.

MATERIALS AND METHODS {#s4}
=====================

Data sources and search {#s4_1}
-----------------------

Relevant articles were thoroughly searched from PubMed, EMBASE and Cochrane Library databases using the following terms: programmed cell death-ligand 1, PD-L1, B7-H1, lung cancer, NSCLC, EGFR, ALK, KRAS and driver genes, from their inception till September 2016. The search was performed with language limitation to English. If the same population was found in different publications, the latest or the most complete articles were included. Once the articles were identified, the references were also searched for extending the search. All potential relevant articles were scanned by two researchers (Yang HT and Chen HJ) independently via the following process: initially excluding duplication by Endnote X7 software, then selecting pertinent articles via screening titles or abstracts and eventually identifying eligible articles through scrutinizing full-texts. Disagreement was resolved by consensus or the third researcher (Xie XH).

Study selection {#s4_2}
---------------

The eligible articles should meet the following criteria: i) all patients had histologically or cytologically confirmed NSCLC; ii) PD-L1 expression as well as one or more driver genes (EGFR, ALK and KRAS) were available; iii) all studies investigated the correlation between positive PD-L1 expression and driver genes mutations in NSCLC and acquired sufficient data; iv) all articles were published in English. Reviews, letters, ongoing studies and insufficient data were excluded.

Data extraction {#s4_3}
---------------

Two researchers (Yang HT and Chen HJ) extracted the following data independently from all eligible studies: the first author\'s name, year of publication, country, gender, smoking status, histological type, PD-L1 expression (positive/negative), driver genes (EGFR, ALK and KRAS status) and OS. When the extracted data existed discrepancy, consultation was held to settle the problem.

Statistical analysis {#s4_4}
--------------------

The pooled data were calculated via Review manager 5.3 software. Analyses were conducted according to gender, smoking status, histological type, driver genes (EGFR, ALK and KRAS status) and OS. The effective value, RR with 95% confidence intervals (95% CIs), was employed to evaluate the correlation between positive PD-L1 expression and driver gene mutations, clinical characteristics in NSCLC. Hazard ratios (HRs) with 95% CIs were extracted from the articles or calculated from survival curves according to Zhou et al method if these data were unavailable \[[@R31]\]. HR\>1 indicated that positive PD-L1 expression had a poor prognosis in NSCLC. Heterogeneity were measured by Chi-square and I-square tests \[[@R32]\]. If *P \<* 0.1 and I^2^ \> 50%, indicating significant heterogeneity, a random effects model was utilized, otherwise, a fixed-effect model was employed \[[@R33]\]. With regard to the diversity of PD-L1 antibodies and nations, subgroup analyses were conducted on Chinese cohort studies, the studies using PD-L1 McAbs or PD-L1 PoAbs, respectively. Publication bias was assessed by funnel plot.
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